Abstract
1. 1. The effectivity of the arabinosylcytosine (araC) derivative, cyclocytidine (cC), against Zajdela hepatoma was evaluated. It was established that the cC effect was dose-dependent. 2. 2. Zajdela hepatoma-bearing rats, given a single dose of 500 mg of cC per kg of body weight, showed an increased life span of 48 and 39%. 3. 3. cC significantly decreased the number of Zajdela hepatoma cells in ascitic fluid and affected the cytochrome content in hepatal mitochondria. 4. 4. The overall cC effect on the hepatal function of normal and hepatectomized liver was marginal, thus making this araC derivative an interesting candidate for further evaluation of its effectivity against non-hematological tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
